English
norskBlar i forfatter "Kjeldsen-Kragh, Jens"
Viser treff 1-9 av 9
-
Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia: comparison of neonatal outcome in treated and nontreated pregnancies
(Journal article; Tidsskriftartikkel; Peer reviewed, 2022-04-29)BACKGROUND: Maternal alloantibodies to human platelet antigen-1a can cause severe intracranial hemorrhage in a fetus or newborn. Although never evaluated in placebo-controlled clinical trials, most Western countries use off-label weekly administration of high-dosage intravenous immunoglobulin in all pregnant women with an obstetrical history of fetal and neonatal alloimmune thrombocytopenia. In ... -
A combined effect of anti-HPA-1a and anti-HLA Class I in pregnancy?
(Journal article; Tidsskriftartikkel; Peer reviewed, 2020-06-30)<i>Background</i> - Maternal anti–human leukocyte antigen (HLA) Class I is commonly detected alongside anti–human platelet antigen (HPA)-1a in fetal and neonatal alloimmune thrombocytopenia (FNAIT). Little is known regarding whether the presence of anti-HLA Class I may exert an additive effect on the risk and severity of FNAIT.<br><br> <i>Methods and Materials</i> - We reanalyzed samples originally ... -
The development of severe Neonatal Alloimmune Thrombocytopenia due to Anti-HPA-1a Antibodies is correlated to maternal ABO genotypes
(Journal article; Tidsskriftartikkel; Peer reviewed, 2012)Background. Maternal alloantibodies against HPA-1a can cross placenta, opsonize foetal platelets, and induce neonatal alloimmune thrombocytopenia (NAIT). In a study of 100, 448 pregnant women in Norway during 1995–2004, 10.6% of HPA-1a negative women had detectable anti-HPA-1a antibodies. Design and Methods. A possible correlation between the maternal ABO blood group phenotype, or underlying genotype, ... -
Fetal exposure to maternal human platelet antigen-1a does not induce tolerance. An analytical observational study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-24)Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a disease that may cause severe bleeding complications with risk of perinatal death or lifelong disability. The main cause of FNAIT is maternal antibodies against human platelet antigen (HPA)-1a. Both fetomaternal bleeding and transplacental trafficking of fetal cells during pregnancy could be the cause of alloimmunization. Persistence of ... -
Fetal/neonatal alloimmune thrombocytopenia: A systematic review of impact of HLA-DRB3∗01:01 on fetal/neonatal outcome
(Journal article; Tidsskriftartikkel; Peer reviewed, 2020-07-27)The most common, severe cases of fetal and neonatal alloimmune thrombocytopenia among whites are caused by antibodies against human platelet antigen 1a (HPA-1a). The aims of this systematic review and meta-analysis are to determine the association between maternal HLA-DRB3*01:01 and: (1) HPA-1a-alloimmunization and (2) neonatal outcome in children born of HPA-1a-immunized women. A systematic ... -
An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2022-12-22)Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associated with the most frequent FNAIT cases. There are no approved therapies for FNAIT prevention or treatment. RLYB211 is a polyclonal HPA-1a hyperimmune IgG being developed to prevent ... -
Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin
(Journal article; Tidsskriftartikkel; Peer reviewed, 2023-08-24)Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition in which maternal alloantibodies to fetal platelets cause fetal thrombocytopenia that may lead to intracranial hemorrhage (ICH). Off-label intravenous immunoglobulin (IVIg) has for 30 years been the standard of care for pregnant women who previously have had a child with FNAIT. The efficacy of this treatment has never ... -
The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depend on both the DRB3*01:01 allele and associated DR-DQ haplotypes
(Journal article; Tidsskriftartikkel; Peer reviewed, 2020-04-16)Alloimmunization against human platelet antigen (HPA)-1a during pregnancy can cause foetal/neonatal alloimmune thrombocytopenia (FNAIT) and severe bleeding in the foetus or newborn and likely depends on several factors. HPA-1a alloimmunization is associated with <i>DRB3*01:01</i>, which is associated with several DR-DQ haplotypes. However, it is not known to what extent these haplotypes contribute ... -
A prospective study of maternal anti-HPA1a antibody level as a potential predictor for alloimmune thrombocytopenia in the newborn
(Journal article; Tidsskriftartikkel; Peer reviewed, 2008)
